How many insider trades does FilingIQ track for IDYA?

FilingIQ tracks 194 Form 4 insider transactions for IDYA (IDEAYA Biosciences, Inc.), covering filings from May 28, 2019 onwards. 1 of those were filed in the last 90 days.

Are IDYA insiders net buyers or net sellers?

Across the full Form 4 history for IDYA, 20 transactions (10%) were open-market purchases and 83 (43%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does IDYA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is IDYA in?

IDEAYA Biosciences, Inc. (IDYA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.67B.

IDYA insider trading

Healthcare

IDEAYA Biosciences, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

194

Last 90 days

Buys / sells

10% / 43%

Market cap

$2.67B

About IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Company website: www.ideayabio.com

IDYA insider activity at a glance

FilingIQ has scored 194 insider transactions for IDYA since May 28, 2019. The most recent filing in our index is dated Mar 2, 2026.

Across the full history, 20 open-market purchases and 83 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on IDYA insider trades is 61.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live IDYA trades on FilingIQ Raw filings on SEC EDGAR

Latest IDYA Form 4 filings

Stone Paul A. Chief Financial Officer

S Aug 29, 2023

Stone Paul A. Chief Financial Officer

S Aug 9, 2023

Throne Jason Chief Legal Officer

S Jul 10, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding IDYA

Logos Global Management LP

$59.69M · 4.8% of AUM

Sofinnova Investments, Inc.

$51.91M · 2.9% of AUM

Frequently asked

How many insider trades does FilingIQ track for IDYA?: FilingIQ tracks 194 Form 4 insider transactions for IDYA (IDEAYA Biosciences, Inc.), covering filings from May 28, 2019 onwards. 1 of those were filed in the last 90 days.
Are IDYA insiders net buyers or net sellers?: Across the full Form 4 history for IDYA, 20 transactions (10%) were open-market purchases and 83 (43%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does IDYA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is IDYA in?: IDEAYA Biosciences, Inc. (IDYA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.67B.

Methodology & sources

Every IDYA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.